|Mr. Scott Raymond Ward MS, B.Sc.||1.85M||N/A||57|
|Mr. Laurence L. Betterley||848.21k||N/A||63|
|Mr. Kevin J. Kenny||1.15M||N/A||52|
|Ms. Laura J. Gillund||628.26k||N/A||56|
|Mr. Jack E. Nielsen||N/A||N/A||N/A|
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. The company sells its products directly to hospitals or office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Cardiovascular Systems, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 6; Compensation: 6.